Glitazones for human nonalcoholic steatohepatitis

Therapeutic Advances in Gastroenterology

Volumn 4, Issue 5, 2011, Pages 325-334

  Pais, Raluca ^a   Moraru, Ioana ^a   Ratziu, Vlad ^a  

^a SORBONNE UNIVERSITÉ   (France)

Author keywords

Fibrosis; Glitazones; Insulin resistance; Insulin sensitizing drugs; Nonalcoholic steatohepatitis; Steatosis

Indexed keywords

ALPHA TOCOPHEROL; GLITAZONE DERIVATIVE; PIOGLITAZONE; PLACEBO; ROSIGLITAZONE;

CARDIOVASCULAR DISEASE; DIET; DRUG EFFICACY; DRUG MECHANISM; DRUG SAFETY; HUMAN; INSULIN RESISTANCE; LIFESTYLE MODIFICATION; META ANALYSIS (TOPIC); NONALCOHOLIC FATTY LIVER; OSTEOPOROSIS; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW; SIDE EFFECT; WEIGHT GAIN;

EID: 80052368721     PISSN: 1756283X     EISSN: 17562648     Source Type: Journal    
DOI: 10.1177/1756283X11409793     Document Type: Review

References (52)

1. Aithal G.P. Thomas J.A. Kaye P.V. Lawson A. Ryder S.D. Spendlove I. et al (2008) Randomized, placebo-controlled trial of pioglitazone in nondiabetic subjects with nonalcoholic steatohepatitis. Gastroenterology 135: 1176–1184.
2. Argo C.K. Northup P.G. Al-Osaimi A.M. Caldwell S.H. (2009) Systematic review of risk factors for fibrosis progression in non-alcoholic steatohepatitis. J Hepatol 51: 371–379.
3. Ascha M.S. Hanouneh I.A. Lopez R. Tamimi T.A. Feldstein A.F. Zein N.N. (2010) The incidence and risk factors of hepatocellular carcinoma in patients with nonalcoholic steatohepatitis. Hepatology 51: 1972–1978.
4. Belfort R. Harrison S.A. Brown K. Darland C. Finch J. Hardies J. et al (2006) A placebo-controlled trial of pioglitazone in subjects with nonalcoholic steatohepatitis. N Engl J Med 355: 2297–2307.
5. Betteridge D.J. (2007) Effects of pioglitazone on lipid and lipoprotein metabolism. Diabetes Obes Metab 9: 640–647.
6. Bugianesi E. Leone N. Vanni E. Marchesini G. Brunello F. Carucci P. et al (2002) Expanding the natural history of nonalcoholic steatohepatitis: From cryptogenic cirrhosis to hepatocellular carcinoma. Gastroenterology 123: 134–140.
7. Bugianesi E. McCullough A.J. Marchesini G. (2005 a) Insulin resistance: a metabolic pathway to chronic liver disease. Hepatology 42: 987–1000.
8. Bugianesi E. Pagotto U. Manini R. Vanni E. Gastaldelli A. de Iasio R. et al (2005 b) Plasma adiponectin in nonalcoholic fatty liver is related to hepatic insulin resistance and hepatic fat content, not to liver disease severity. J Clin Endocrinol Metab 90: 3498–3504.
9. Caldwell S.H. Crespo D.M. (2004) The spectrum expanded: cryptogenic cirrhosis and the natural history of non-alcoholic fatty liver disease. J Hepatol 40: 578–584.
10. Cusi K. (2009) Role of insulin resistance and lipotoxicity in non-alcoholic steatohepatitis. Clin Liver Dis 13: 545–563.
11. Dam-Larsen S. Franzmann M. Andersen I.B. Christoffersen P. Jensen L.B. Sorensen T.I. et al (2004) Long term prognosis of fatty liver: risk of chronic liver disease and death. Gut 53: 750–755.
12. Dormandy J.A. Charbonnel B. Eckland D.J. Erdmann E. Massi-Benedetti M. Moules I.K. et al (2005) Secondary prevention of macrovascular events in patients with type 2 diabetes in the PROactive Study (PROspective pioglit Azone Clinical Trial In macro Vascular Events): a randomised controlled trial. Lancet 366: 1279–1289.
13. Fabbrini E. Magkos F. Mohammed B.S. Pietka T. Abumrad N.A. Patterson B.W. et al (2009) Intrahepatic fat, not visceral fat, is linked with metabolic complications of obesity. Proc Natl Acad Sci U S A 106: 15430–15435.
14. Feldstein A.E. Papouchado B.G. Angulo P. Sanderson S. Adams L. Gores G.J. (2005) Hepatic stellate cells and fibrosis progression in patients with nonalcoholic fatty liver disease. Clin Gastroenterol Hepatol 3: 384–389.
15. Fracanzani A.L. Valenti L. Bugianesi E. Andreoletti M. Colli A. Vanni E. et al (2008) Risk of severe liver disease in nonalcoholic fatty liver disease with normal aminotransferase levels: a role for insulin resistance and diabetes. Hepatology 48: 792–798.
16. Gastaldelli A. Harrison S.A. Belfort-Aguilar R. Hardies L.J. Balas B. Schenker S. et al (2009 a) Importance of changes in adipose tissue insulin resistance to histological response during thiazolidinedione treatment of patients with nonalcoholic steatohepatitis. Hepatology 50: 1087–1093.
17. Gastaldelli A. Kozakova M. Hojlund K. Flyvbjerg A. Favuzzi A. Mitrakou A. et al (2009 b) Fatty liver is associated with insulin resistance, risk of coronary heart disease, and early atherosclerosis in a large European population. Hepatology 49: 1537–1544.
18. Gerstein H.C. Yusuf S. Bosch J. Pogue J. Sheridan P. Dinccag N. et al (2006) Effect of rosiglitazone on the frequency of diabetes in patients with impaired glucose tolerance or impaired fasting glucose: a randomised controlled trial. Lancet 368: 1096–1105.
19. Grey A. (2008) Skeletal consequences of thiazolidinedione therapy. Osteoporos Int 19: 129–137.
20. Home P.D. Pocock S.J. Beck-Nielsen H. Curtis P.S. Gomis R. Hanefeld M. et al (2009) Rosiglitazone evaluated for cardiovascular outcomes in oral agent combination therapy for type 2 diabetes (RECORD): a multicentre, randomised, open-label trial. Lancet 373: 2125–2135.
21. Home P.D. Pocock S.J. Beck-Nielsen H. Gomis R. Hanefeld M. Jones N.P. et al (2007) Rosiglitazone evaluated for cardiovascular outcomes–an interim analysis. N Engl J Med 357: 28–38.
22. Kahn S.E. Haffner S.M. Heise M.A. Herman W.H. Holman R.R. Jones N.P. et al (2006) Glycemic durability of rosiglitazone, metformin, or glyburide monotherapy. N Engl J Med 355: 2427–2443.
23. Lincoff A.M. Wolski K. Nicholls S.J. Nissen S.E. (2007) Pioglitazone and risk of cardiovascular events in patients with type 2 diabetes mellitus: a meta-analysis of randomized trials. JAMA 298: 1180–1188.
24. Loke Y.K. Singh S. Furberg C.D. (2009) Long-term use of thiazolidinediones and fractures in type 2 diabetes: a meta-analysis. CMAJ 180: 32–39.
25. Lutchman G. Modi A. Kleiner D.E. Promrat K. Heller T. Ghany M. et al (2007) The effects of discontinuing pioglitazone in patients with nonalcoholic steatohepatitis. Hepatology 46: 424–429.
26. Lutchman G. Promrat K. Kleiner D.E. Heller T. Ghany M.G. Yanovski J.A. et al (2006) Changes in serum adipokine levels during pioglitazone treatment for nonalcoholic steatohepatitis: relationship to histological improvement. Clin Gastroenterol Hepatol 4: 1048–1052.
27. Malhi H. Gores G.J. (2008) Molecular mechanisms of lipotoxicity in nonalcoholic fatty liver disease. Semin Liver Dis 28: 360–369.
28. Marchesini G. Bugianesi E. Forlani G. Cerrelli F. Lenzi M. Manini R. et al (2003) Nonalcoholic fatty liver, steatohepatitis, and the metabolic syndrome. Hepatology 37: 917–923.
29. Mazzone T. Meyer P.M. Feinstein S.B. Davidson M.H. Kondos G.T. D'Agostino R.B. Sr et al (2006) Effect of pioglitazone compared with glimepiride on carotid intima-media thickness in type 2 diabetes: a randomized trial. JAMA 296: 2572–2581.
30. Miyazaki Y. Mahankali A. Matsuda M. Mahankali S. Hardies J. Cusi K. et al (2002) Effect of pioglitazone on abdominal fat distribution and insulin sensitivity in type 2 diabetic patients. J Clin Endocrinol Metab 87: 2784–2791.
31. Nayak N.C. Vasdev N. Saigal S. Soin A.S. (2010) End-stage nonalcoholic fatty liver disease: evaluation of pathomorphologic features and relationship to cryptogenic cirrhosis from study of explant livers in a living donor liver transplant program. Hum Pathol 41: 425–430.
32. Neuschwander-Tetri B.A. (2010 a) Hepatic lipotoxicity and the pathogenesis of nonalcoholic steatohepatitis: the central role of nontriglyceride fatty acid metabolites. Hepatology 52: 774–788.
33. Neuschwander-Tetri B.A. (2010 b) Nontriglyceride hepatic lipotoxicity: the new paradigm for the pathogenesis of NASH. Curr Gastroenterol Rep 12: 49–56.
34. Neuschwander-Tetri B.A. Brunt E.M. Wehmeier K.R. Oliver D. Bacon B.R. (2003) Improved nonalcoholic steatohepatitis after 48 weeks of treatment with the PPAR-gamma ligand rosiglitazone. Hepatology 38: 1008–1017.
35. Nissen S.E. Nicholls S.J. Wolski K. Nesto R. Kupfer S. Perez A. et al (2008) Comparison of pioglitazone vs glimepiride on progression of coronary atherosclerosis in patients with type 2 diabetes: the PERISCOPE randomized controlled trial. JAMA 299: 1561–1573.
36. Nissen S.E. Wolski K. (2007) Effect of rosiglitazone on the risk of myocardial infarction and death from cardiovascular causes. N Engl J Med 356: 2457–2471.
37. Ong J. Pitts A. Younossi Z. (2008) Increased overall mortality and liver-related mortality in nonalcoholic fatty liver disease. J Hepatol 49: 608–612.
38. Paradis V. Zalinski S. Chelbi E. Guedj N. Degos F. Vilgrain V. et al (2009) Hepatocellular carcinomas in patients with metabolic syndrome often develop without significant liver fibrosis: a pathological analysis. Hepatology 49: 851–859.
39. Petta S. Muratore C. Craxi A. (2009) Non-alcoholic fatty liver disease pathogenesis: the present and the future. Dig Liver Dis 41: 615–625.
40. Promrat K. Lutchman G. Uwaifo G.I. Freedman R.J. Soza A. Heller T. et al (2004) A pilot study of pioglitazone treatment for nonalcoholic steatohepatitis. Hepatology 39: 188–196.
41. Ratziu V. Bellentani S. Cortez-Pinto H. Day C. Marchesini G. (2010 a) A position statement on NAFLD/NASH based on the EASL 2009 special conference. J Hepatol 53: 372–384.
42. Ratziu V. Bonyhay L. Di Martino V. Charlotte F. Cavallaro L. Sayegh-Tainturier M.H. et al (2002) Survival, liver failure, and hepatocellular carcinoma in obesity-related cryptogenic cirrhosis. Hepatology 35: 1485–1493.
43. Ratziu V. Caldwell S. Neuschwander-Tetri B.A. (2010 b) Therapeutic trials in nonalcoholic steatohepatitis: Insulin sensitizers and related methodological issues. Hepatology 52: 2206–2215.
44. Ratziu V. Charlotte F. Bernhardt C. Giral P. Halbron M. Lenaour G. et al (2010 c) Long-term efficacy of rosiglitazone in nonalcoholic steatohepatitis: Results of the fatty liver improvement by rosiglitazone therapy (FLIRT 2) extension trial. Hepatology 51: 445–453.
45. Ratziu V. Giral P. Jacqueminet S. Charlotte F. Hartemann-Heurtier A. Serfaty L. et al (2008) Rosiglitazone for nonalcoholic steatohepatitis: one-year results of the randomized placebo-controlled Fatty Liver Improvement with Rosiglitazone Therapy (FLIRT) Trial. Gastroenterology 135: 100–110.
46. Ratziu V. Zelber-Sagi S. (2009) Pharmacologic therapy of non-alcoholic steatohepatitis. Clin Liver Dis 13: 667–688.
47. Sanyal A.J. Chalasani N. Kowdley K.V. McCullough A. Diehl A.M. Bass N.M. et al (2010) Pioglitazone, Vitamin E, or Placebo for Nonalcoholic Steatohepatitis. N Engl J Med 362: 1675–1685.
48. Sanyal A.J. Mofrad P.S. Contos M.J. Sargeant C. Luketic V.A. Sterling R.K. et al (2004) A pilot study of vitamin E versus vitamin E and pioglitazone for the treatment of nonalcoholic steatohepatitis. Clin Gastroenterol Hepatol 2: 1107–1115.
49. Sharma A.M. Staels B. (2007) Review: Peroxisome proliferator-activated receptor gamma and adipose tissue–understanding obesity-related changes in regulation of lipid and glucose metabolism. J Clin Endocrinol Metab 92: 386–395.
50. Soderberg C. Stal P. Askling J. Glaumann H. Lindberg G. Marmur J. et al (2010) Decreased survival of subjects with elevated liver function tests during a 28-year follow-up. Hepatology 51: 595–602.
51. Starley B.Q. Calcagno C.J. Harrison S.A. (2010) Nonalcoholic fatty liver disease and hepatocellular carcinoma: a weighty connection. Hepatology 51: 1820–1832.
52. Yamaguchi K. Yang L. McCall S. Huang J. Yu X.X. Pandey S.K. et al (2007) Inhibiting triglyceride synthesis improves hepatic steatosis but exacerbates liver damage and fibrosis in obese mice with nonalcoholic steatohepatitis. Hepatology 45: 1366–1374.